Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Masszi, Tamás
[Clear All Filters]
2022
Schjesvold FH
,
Dimopoulos M-A
,
Delimpasi S
,
Robak P
,
Coriu D
,
Legiec W
,
Pour L
,
Spicka I
,
Masszi T
,
Doronin V
, et al.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Lancet Haematol. 2022.
PubMed
Google Scholar
2020
Di Bacco A
,
Bahlis NJ
,
Munshi NC
,
Avet-Loiseau H
,
Masszi T
,
Viterbo L
,
Pour L
,
Ganly P
,
Cavo M
,
Langer C
, et al.
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Eur J Haematol. 2020.
PubMed
Google Scholar
2019
Beelen DWilhelm
,
Trenschel R
,
Stelljes M
,
Groth C
,
Masszi T
,
Reményi P
,
Wagner-Drouet E-M
,
Hauptrock B
,
Dreger P
,
Luft T
, et al.
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3
. Lancet Haematol. 2019.
PubMed
Google Scholar
2018
Lupsa N
,
Érsek B
,
Horváth A
,
Bencsik A
,
Lajkó E
,
Silló P
,
Oszvald Á
,
Wiener Z
,
Reményi P
,
Mikala G
, et al.
Skin-homing CD8+ T cells preferentially express GPI-anchored peptidase inhibitor 16, an inhibitor of cathepsin K.
Eur J Immunol. 2018.
PubMed
Google Scholar
2016
Palumbo A
,
Chanan-Khan A
,
Weisel K
,
Nooka AK
,
Masszi T
,
Beksac M
,
Spicka I
,
Hungria V
,
Munder M
,
Mateos MV
, et al.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016;375(8):754-766.
PubMed
Google Scholar
2015
Moskowitz CH
,
Nademanee A
,
Masszi T
,
Agura E
,
Holowiecki J
,
Abidi MH
,
Chen AI
,
Stiff P
,
Gianni AM
,
Carella A
, et al.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015.
PubMed
Google Scholar
Dimopoulos MA
,
Moreau P
,
Palumbo A
,
Joshua D
,
Pour L
,
Hajek R
,
Facon T
,
Ludwig H
,
Oriol A
,
Goldschmidt H
, et al.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol. 2015.
PubMed
Google Scholar
Pardanani A
,
Harrison C
,
Cortes JE
,
Cervantes F
,
Mesa RA
,
Milligan D
,
Masszi T
,
Mishchenko E
,
Jourdan E
,
Vannucchi AM
, et al.
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
JAMA Oncol. 2015.
PubMed
Google Scholar
2014
Reményi P
,
Gopcsa L
,
Marton I
,
Réti M
,
Mikala G
,
Pető M
,
Barta A
,
Bátai A
,
Farkas Z
,
Borbényi Z
, et al.
Peripheral Blood Stem Cell Mobilization and Engraftment after Autologous Stem Cell Transplantation with Biosimilar rhG-CSF.
Adv Ther. 2014.
PubMed
Google Scholar
2013
Nagler A
,
Rocha V
,
Labopin M
,
Unal A
,
Ben Othman T
,
Campos A
,
Volin L
,
Poire X
,
Aljurf M
,
Masszi T
, et al.
Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki
. J Clin Oncol. 2013.
PubMed
Google Scholar